Correlations between serum and CSF pNfH levels in ALS, FTD and controls: a comparison of three analytical approaches

Autor: Rebecca Schüle, Kina Höglund, Jens Kuhle, Christian Barro, Kaj Blennow, Fani Pujol-Calderón, Christian Deuschle, Matthis Synofzik, Elke Stransky, Zuzanna Michalak, Henrik Zetterberg, Andreas Jeromin, Carlo Wilke
Rok vydání: 2019
Předmět:
Adult
blood [Frontotemporal Dementia]
Male
0301 basic medicine
Neurofilament
cerebrospinal fluid [Huntington Disease]
methods [Clinical Laboratory Techniques]
Clinical Biochemistry
Intermediate Filaments
analysis [Neurofilament Proteins]
blood [Neurofilament Proteins]
cerebrospinal fluid [Frontotemporal Dementia]
blood [Amyotrophic Lateral Sclerosis]
03 medical and health sciences
blood [Alzheimer Disease]
0302 clinical medicine
Cerebrospinal fluid
Neuronal damage
medicine
Humans
ddc:610
Phosphorylation
Amyotrophic lateral sclerosis
Aged
metabolism [Serum]
blood [Biomarkers]
business.industry
blood [Huntington Disease]
Biochemistry (medical)
Reproducibility of Results
General Medicine
Middle Aged
Control subjects
medicine.disease
cerebrospinal fluid [Alzheimer Disease]
cerebrospinal fluid [Neurofilament Proteins]
030104 developmental biology
Immunology
Disease Progression
Biomarker (medicine)
Neuronal cytoskeleton
cerebrospinal fluid [Amyotrophic Lateral Sclerosis]
Female
business
030217 neurology & neurosurgery
Frontotemporal dementia
Zdroj: Clinical chemistry and laboratory medicine 57(10), 1556-1564 (2019). doi:10.1515/cclm-2019-0015
ISSN: 1437-4331
1434-6621
DOI: 10.1515/cclm-2019-0015
Popis: Background Phosphorylated neurofilament heavy (pNfH), a neuronal cytoskeleton protein, might provide a promising blood biomarker of neuronal damage in neurodegenerative diseases (NDDs). The best analytical approaches to measure pNfH levels and whether serum levels correlate with cerebrospinal fluid (CSF) levels in NDDs remain to be determined. Methods We here compared analytical sensitivity and reliability of three novel analytical approaches (homebrew Simoa, commercial Simoa and ELISA) for quantifying pNfH in both CSF and serum in samples of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) and control subjects. Results While all three assays showed highly correlated CSF measurements, Simoa assays also yielded high between-assay correlations for serum measurements (ϱ = 0.95). Serum levels also correlated strongly with CSF levels for Simoa-based measurements (both ϱ = 0.62). All three assays allowed distinguishing ALS from controls by increased CSF pNfH levels, and Simoa assays also by increased serum pNfH levels. pNfH levels were also increased in FTD. Conclusions pNfH concentrations in CSF and, if measured by Simoa assays, in blood might provide a sensitive and reliable biomarker of neuronal damage, with good between-assay correlations. Serum pNfH levels measured by Simoa assays closely reflect CSF levels, rendering serum pNfH an easily accessible blood biomarker of neuronal damage in NDDs.
Databáze: OpenAIRE